Johnson & Johnson agrees to resolve ovarian talc litigation with $5.5 billion commitment
Johnson & Johnson said it reached an agreement to comprehensively resolve the remaining ovarian talc litigation, covering about 76,000 claims, with a $5.5 billion commitment by the company. The deal is conditioned on participation by at least 95% of the remaining claims, and the company said it continues to deny that its talc products cause cancer.
Key points
- Company commitment of $5.5 billion, with the first payment of no more than $3 billion due in 2027 and no additional payments due before 2028
- Agreement conditioned on participation of at least 95% of the remaining claims, including lead plaintiff firms in federal MDL and state court cases
- Announced July 27, 2026, following a July 22, 2026 MDL court order requiring plaintiffs to show why remaining claims should not be dismissed
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.